Entries by oslocancer

Nordic Life Science Days and ECCP2014 merge

Oslo Cancer Cluster and French partner Cancer-Bio-Santé are joining forces with SwedenBio to offer the global Life Science industry the largest partnering conference in the Nordics – Nordic Life Science Days featuring the 6th European Cancer Cluster Partnering. Already now oncology biotechs, early stage companies and academics may submit an application for presenting at NLSDays-ECCP […]

Presentations from cancer nanomedicine seminar

Friday January 31 Oslo Cancer Cluster, SINTEF, NTNU, Oslo University Hospital and the Norwegian Cancer Society  invite Norwegian media and other interested parties to join a breakfast seminar on nano cancer medicine. The seminar is held in conjunction with 12 similair events across the whole of Europe in relation to Nano World Cancer Day. Below […]

Excellent evaluation of Oslo Cancer Cluster

The six year evaluation of Oslo Cancer Cluster as a Norwegian Centre of Expertise concludes that Oslo Cancer Cluster is a strong biotech cluster, well positioned within the global oncology industry. “This plays well with our ambition to take the step up a level and become a Global Centre of Excellence,” says Jónas Einarsson, acting CEO […]

Marketing authorisation for Bayer/Algeta`s prostate cancer treatment

Oslo Cancer Cluster member Bayer HealthCare announced Monday December 9th that they just received the marketing approval for Xofigo® (radium Ra 223 dichloride) by the Norwegian Medicines Agency. The approval came approximately one month after the European Commission granted marketing authorization in the EU for Xofigo® on November 15 2013.

Horizon 2020: Major possibilities

Horizon 2020 is the new European Framework Program for Research and Innovation. Oslo Cancer Cluster encourage our members to take a closer look at the possibilities Horizon 2020 represents for funding R&D oncology projects and also taking part in international networks.

Inven2 strike major deal

Inven2 grants exclusive worldwide license to its epidermal growth factor receptor (EGFR) inhibitors patent portfolio to Merck. Researchers and clinicians at Sørlandet Hospital have discovered that the EGFR inhibitors may play a vital role as a pain reliever for so called neuropathic pain.

Pleased with the political platform

The new government of Norway has launched their political platform. Oslo Cancer Cluster have reviewed the political platform document. We are overall very pleased with the initiatives that concerns research, knowledge, education, business and R&D.

National Cancer Drugs Fund

Oslo Cancer Cluster, the Norwegian Cancer Society and the Association of the Pharmaceutical Industry in Norway join forces in pushing for a new cancer drugs fund. The purpose of the fund is to ensure equal and quicker access to new approved cancer drugs in Norway.   A cancer drugs fund would cover the costs of […]